0001986426-23-000001.txt : 20230822 0001986426-23-000001.hdr.sgml : 20230822 20230822123735 ACCESSION NUMBER: 0001986426-23-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20230822 DATE AS OF CHANGE: 20230822 EFFECTIVENESS DATE: 20230822 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Gladius Therapeutics, Inc. CENTRAL INDEX KEY: 0001986426 IRS NUMBER: 922978883 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-490377 FILM NUMBER: 231192057 BUSINESS ADDRESS: STREET 1: B+LABS, FLOOR 2 STREET 2: 2929 ARCH STREET CITY: PHILADELPHIA STATE: PA ZIP: 19104 BUSINESS PHONE: 215-518-3590 MAIL ADDRESS: STREET 1: B+LABS, FLOOR 2 STREET 2: 2929 ARCH STREET CITY: PHILADELPHIA STATE: PA ZIP: 19104 D 1 primary_doc.xml X0708 D LIVE 0001986426 Gladius Therapeutics, Inc. B+LABS, FLOOR 2 2929 ARCH STREET PHILADELPHIA PA PENNSYLVANIA 19104 215-518-3590 DELAWARE None None Corporation true 2023 Michael Seiden B+LABS, FLOOR 2 2929 Arch Street Philadelphia PA PENNSYLVANIA 19104 Executive Officer Director Promoter Other Health Care Decline to Disclose 06b false 2023-08-14 false true true true false 0 300000 300000 0 false 4 0 0 0 true Proceeds will be used for working capital, which may include normal compensation to executive officers. false Gladius Therapeutics, Inc. Michael Seiden Michael Seiden President 2023-08-21